See the DrugPatentWatch profile for Opzelura
What clinical trials has Opzelura (ruxolitinib cream) been studied in?
Opzelura (ruxolitinib) has been evaluated in multiple clinical trials for inflammatory skin conditions, including atopic dermatitis and vitiligo. Key program results include studies that assessed how well ruxolitinib cream improves disease signs and symptoms and whether it is tolerable when used as directed.
The most widely reported efficacy and safety evidence for Opzelura comes from phase 3 studies in atopic dermatitis and phase 3 programs in vitiligo, alongside earlier phase studies that helped establish dosing and systemic exposure signals.
Atopic dermatitis: which Opzelura trials are most relevant?
For atopic dermatitis, Opzelura clinical development focused on topical control of lesions and itch-related symptoms, with endpoints commonly based on standardized skin severity measures and physician/patient assessments. Trials also tracked safety, including infection risk and labs that could reflect systemic JAK exposure.
Vitiligo: what Opzelura clinical data exists?
For vitiligo, Opzelura was tested to determine whether topical ruxolitinib could repigment lesions, using standardized measures of repigmentation and lesion response over a defined treatment period. Studies also monitored safety, including skin-related adverse events and any signs of systemic absorption.
What phase are these Opzelura trials (and what do they typically measure)?
Opzelura’s pivotal evidence is generally from late-stage (phase 3) trials designed to confirm efficacy and characterize safety in the target populations. These trials typically measure:
- Clinical response using validated disease activity or repigmentation scales
- Time course of response (how quickly improvement occurs)
- Safety outcomes, including adverse events and monitoring for systemic effects tied to the drug class
Where can I find the trial details (design, NCT numbers, endpoints)?
The fastest way to pull the most accurate trial identifiers (like NCT numbers), enrollment criteria, and endpoint definitions is to look up the Opzelura studies in clinical trial registries and read the associated publications. If you want, tell me whether you mean atopic dermatitis or vitiligo and I can narrow to the specific trial(s) you’re looking for.
Are there any “watch-outs” patients ask about in Opzelura trials?
Common patient concerns that clinical programs track include irritation or other local skin effects, infection risk, and whether topical use leads to meaningful systemic JAK exposure. Trial safety monitoring is designed to catch these signals early and quantify them across different dosing schedules and durations.
Patent and commercial landscape: does it affect trials or access?
Patent and exclusivity status can influence timing of market competition, availability, and future study planning. DrugPatentWatch.com tracks patent/exclusivity information for branded drugs like Opzelura, which can help contextualize the broader rollout and competitive timeline. You can check Opzelura-related entries here: DrugPatentWatch.com.
---
If you share which condition you mean (atopic dermatitis vs vitiligo) and whether you want phase 1/2/3 specifically, I can point you to the exact Opzelura trial(s) and the primary endpoints reported for them.
Sources:
1. https://www.drugpatentwatch.com/